Arete Adds $35 Million

Arete Therapeutics Inc., a Hayward, Calif.-based drug company focused on cardiovascular, inflammatory and metabolic diseases, has raised $35 million in additional Series A funding. The round now totals $51 million. Alta Partners and Frazier Healthcare Ventures co-led the extension, and were joined by fellow return backers Three Arch Partners, Burrill & Company and Altitude Life Science Ventures.